If you are interested in participating in the BPH Global Registry project, please click this link to submit your institution and we will contact you as soon as possible.
Already signed up? Follow this link to navigate to the BPH Registry login page:
In the links below, you will find resources for the principal investigators, and the participating physicians:
A Global Registry of Treatments and Outcomes for Benign Prostatic Hyperplasia
Lead Investigator:
Mihir Desai, MD, MPH
Professor of Urology
Director, Robotic Urologic Surgery
University of Southern California
1516 San Pablo St, Ste 3500, Los Angeles, CA 90033
Tel.: +1 (323) 865-3700
Rationale: There has been a significant expansion in the number of approved medical and surgical interventions with symptomatic BPH. There is a significant research interest in monitoring clinical outcomes including improvements in urinary function, impact on sexual function, postoperative morbidity as well as retreatment. A registry such as what is proposed provides real time data accounting for relevant baseline demographic characteristics in this population of men. The SIU (Société Internationale d’Urologie) is an academic organisation that is uniquely positioned to initiate such a registry because of its global outreach including countries where data are lacking.
Primary Objective: To assess peri-operative and functional outcomes of various medical and surgical interventions for symptomatic BPH in a global population.
Secondary Objective: To assess demographic characteristics of patients undergoing medical or surgical therapy for BPH at a global level.
Study design: A multicentre observational cohort study.
Study population: Male patients, ≥18 years of age, presenting at their physician’s office with LUTS/BPH, who undergo medical/surgical treatment.
Intervention: All patients receive standard care for their symptoms according to their physician’s practice.
Main study parameters/endpoints: There is no endpoint for follow-up. After 1 year of data collection, the registry will undergo an independent audit to verify data quality and consistency. After 3 years, a publication based on the results thus far will be submitted to appropriate journals.
Nature and extent of the burden and risks associated with participation, benefit, and group relatedness: The registry is an addition to the standard treatment and does not affect the treatment. Therefore, no negative outcomes or risks are expected.
For more information about this pilot study, please visit the study page of uCARE.
